Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 10/2013

01-07-2013 | Adis Drug Evaluation

Ceftaroline Fosamil: A Review of its Use in the Treatment of Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia

Author: James E. Frampton

Published in: Drugs | Issue 10/2013

Login to get access

Abstract

Ceftaroline, the active metabolite of the prodrug ceftaroline fosamil (Zinforo™, Teflaro®), is an advanced-generation, parenteral cephalosporin with broad-spectrum antibacterial activity in vitro against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and multidrug resistant Streptococcus pneumoniae and Gram-negative bacteria, including Haemophilus influenzae and Moraxella catarrhalis, but not Pseudomonas aeruginosa. Ceftaroline has demonstrated a low potential for the selection of resistance in vitro for drug-resistant Gram-positive organisms, including MRSA, as well as for Gram-negative respiratory pathogens. In pivotal phase III studies, intravenous ceftaroline fosamil demonstrated noninferiority to intravenous vancomycin plus aztreonam in patients hospitalized with complicated skin and soft tissue infections (cSSTIs) and intravenous ceftriaxone in patients hospitalized with community-acquired pneumonia (CAP) [Pneumonia Outcomes Research Team (PORT) risk class III or IV]; however, patients with CAP admitted to the intensive care unit were not evaluated. Ceftaroline fosamil was generally well tolerated in these trials, with an adverse event profile similar to that of other cephalosporins. Diarrhoea was the most commonly reported adverse event; however, the risk of Clostridium difficile-associated diarrhoea with ceftaroline fosamil appeared to be low. Potential limitations of the drug include the lack of an oral formulation and the requirement for twice-daily administration. Nonetheless, ceftaroline fosamil represents an attractive option (either alone or in combination with other agents) for the initial empirical treatment of patients hospitalized with cSSTIs (including those with suspected MRSA infection) or CAP (PORT risk class III or IV) who require intravenous antimicrobial therapy. As with all antibacterial agents, ceftaroline fosamil should be used in accordance with good antimicrobial stewardship.
Literature
1.
Lodise T, Low DE. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Drugs. 2012;72(11):1473–93.PubMedCrossRef
2.
Garrison MW. Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA. Expert Rev Anti-Infect Ther. 2012;10(10):1087–103.PubMedCrossRef
3.
Casapao AM, Steed ME, Levine DP, et al. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection. Expert Opin Pharmacother. 2012;13(8):1177–86.PubMedCrossRef
4.
Poon H, Chang MH, Fung HB. Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Ther. 2012;34(4):743–65.PubMedCrossRef
5.
Steed ME, Rybak MJ. Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens. Pharmacotherapy. 2010;30(4):375–89.PubMedCrossRef
6.
Barbour A, Schmidt S, Rand KH, et al. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimcrob Agents. 2009;34(1):1–7.CrossRef
7.
Kollef MH. New antimicrobial agents for methicillin-resistant Staphylococcus aureus. Crit Care Resusc. 2009;11(4):282–6.PubMed
8.
Zhanel GG, Sniezek G, Schweizer F, et al. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs. 2009;69(7):809–31.PubMedCrossRef
9.
Laudano JB. Ceftaroline fosamil: a new broad-spectrum cephalosporin. J Antimicrob Chemother. 2011;66(Suppl. 3):iii11–8.
10.
11.
12.
Villegas-Estrada A, Lee M, Hesek D, et al. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP2a by two anti-MRSA beta-lactam antibiotics. J Am Chem Soc. 2008;130(29):9212–3.PubMedCrossRef
13.
Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2010;54(5):1670–7.PubMedCrossRef
14.
Moisan H, Pruneau M, Malouin F. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother. 2010;65(4):713–6.PubMedCrossRef
15.
Grebe T, Hakenbeck R. Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of beta-lactam antibiotics. Antimicrob Agents Chemother. 1996;40:829–34.PubMed
16.
Krauss J, van der Linden M, Grebe T, et al. Penicillin-binding proteins 2x and 2b as primary PBP targets in Streptococcus pneumoniae. Microb Drug Resist. 1996;2:183–6.PubMedCrossRef
17.
Sader HS, Biek D, Critchley I, et al. Ceftaroline activity against clinical isolates from United States hospitals: results from the 2011 Assessing Worldwide Antimicrobial Resistance Evaluation programme (AWARE) (abstract no. P1552 plus poster). 22nd European Congress of Clinical Microbiology and Infectious Diseases; 31 Mar–3 Apr 2012; London.
18.
Sader HS, Farrell DJ, Flamm RK, et al. Antimicrobial activity of ceftaroline and comparator agents against contemporary (2010) Staphylococcus aureus isolates from Europe and South Africa (abstract no. P1881 plus poster). 22nd European Congress of Clinical Microbiology and Infectious Diseases; 31 Mar–3 Apr 2012; London.
19.
Farrell DJ, Sader HS, Flamm RK, et al. Antimicrobial activity of ceftaroline and comparator agents against contemporary (2010) Streptococcus pneumoniae from Europe and South Africa (abstract no. P1564 plus poster). 22nd European Congress of Clinical Microbiology and Infectious Diseases; 31 Mar–3 Apr 2012; London.
20.
Farrell DJ, Flamm RK, Sader HS, et al. Spectrum and potency of ceftaroline against leading pathogens causing skin and soft-tissue infections in Europe (2010). Int J Antimcrob Agents. 2013;41(4):337–42.CrossRef
21.
Jones RN, Farrell DJ, Mendes RE, et al. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. J Antimicrob Chemother. 2011;66(Suppl. 3):iii69–80.
22.
Farrell DJ, Moet GJ, Rhomberg PR, et al. Activity of ceftaroline against recent (2009) and multidrug-resistant Streptococcus pneumoniae isolates from Europe and the United States (abstract no. P1877 plus poster). 20th European Congress of Clinical Microbiology and Infectious Diseases; 10–13 Apr 2010; Vienna.
23.
Biedenbach DJ, Sader HS, Flamm RK, et al. Ceftaroline activity tested against pathogens associated with acute bacterial skin and skin structure infections (ABSSSI) isolated from Latin American medical centers (2010) (abstract no. C2-123 plus poster). 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 9–12 Sept 2012; San Francisco (CA).
24.
Sader HS, Flamm RK, Jones RN. Antimicrobial activity of ceftaroline tested against pathogens associated with acute bacterial skin and skin structure infections (ABSSSI) collected in China and Hong Kong (2010) (abstract no. PSI-037 plus poster). 13th Asia-Pacific Congress of Clinical Microbiology and Infection; 25–28 Oct 2012; Beijing.
25.
Castanheira M, Jones RN, Sader HS. In vitro activity of ceftaroline tested against leading Gram-positive and -negative European bacterial pathogens collected in 2009 (abstract no. P1876 plus poster). 20th European Congress of Clinical Microbiology and Infectious Diseases; 10–13 Apr 2010; Vienna.
26.
Flamm R, Sader HS, Jones RN. Activity of ceftaroline tested against respiratory tract infection pathogens from China and Hong Kong (2010) (abstract no. PSI-038 plus poster). 13th Asia-Pacific Congress of Clinical Microbiology and Infection; 25–28 Oct 2012; Beijing.
27.
Jones RN, Mendes RE, Sader HS. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J Antimicrob Chemother. 2010;65(Suppl. 4):iv17–31.
28.
Flamm RK, Sader HS, Farrell DJ, et al. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program. Antimicrob Agents Chemother. 2012;56(6):2933–40.PubMedCrossRef
29.
Jacobs MR, Good CE, Windau AR, et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 2010;54(6):2716–9.PubMedCrossRef
30.
Sader HS, Moet G, Jones RN. In vitro activity of ceftaroline tested against recent clinical isolates from the United States (USA) (abstract no. 894 plus poster). 47th Annual Meeting of the Infectious Diseases Society of America; 29 Oct–1 Nov 2009; Philadelphia (PA).
31.
Farrell DJ, Flamm RK, Jones RN, et al. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). Diagn Microbiol Infect Dis. 2013;75:86–8.PubMedCrossRef
32.
Sader HS, Flamm RK, Jones RN. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections from the Asia-Pacific region and South Africa. Diagn Microbiol Infect Dis. 2013;76(1):61–8.PubMedCrossRef
33.
Flamm RK, Sader HS, Jones RN. Activity of ceftaroline against the leading community-acquired respiratory tract infection pathogens in Europe and the Mediterranean region, 2011 (abstract no. P1622 plus poster). 23rd European Congress of Clinical Microbiology and Infectious Disease; 27–30 Apr 2013; Berlin.
34.
Sader HS, Flamm RK, Jones RN. Antimicrobial activity of ceftaroline and comparator agents tested against organisms causing skin and soft tissue infections in European medical centres (2011) (abstract no. P1619 plus poster). 23rd European Congress of Clinical Microbiology and Infectious Disease; 27–30 Apr 2013; Berlin.
35.
Biek D, Krause K, Critchley I. The in vitro activity of ceftaroline against isolates from the 2008 British Society for Antimicrobial Chemotherapy Bacteraemia Surveillance programme (abstract no. P1171 plus poster). 21st European Congress of Clinical Microbiology and Infectious Diseases; 7–10 May 2011; Milan.
36.
Karlowsky JA, Adam HJ, Decorby MR, et al. In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009. Antimicrob Agents Chemother. 2011;55(6):2837–46.PubMedCrossRef
37.
Green K, McGeer A, Rudnick W, et al. In vitro activity of ceftaroline and comparative agents against multidrug-resistant clinical isolates of Streptococcus pneumoniae collected from an ongoing Canada-wide surveillance program: 2008 to 2011 (abstract no. P1562 plus poster). 22nd European Congress of Clinical Microbiology and Infectious Diseases; 31 Mar–3 Apr 2012; London.
38.
Kresken M, Körber-Irrgang B, on behalf of the German Ceftarolin Study Group. In vitro activity of ceftaroline against Gram-positive and Gram-negative pathogens obtained from hospitalized, skin-infected patients in Germany, 2011–2012 (abstract no. P1618 plus poster). 23rd European Congress of Clinical Microbiology and Infectious Disease; 27–30 Apr 2013; Berlin.
39.
Morrissey I, Leakey A, Blackman Northwood j. In vitro activity of ceftaroline and comparator antimicrobials against European and Middle East isolates from complicated skin and skin-structure infections collected in 2008–2009. Int J Antimicrob Agents. 2012;40:227–34.PubMedCrossRef
40.
Morrissey I, Leakey A. Activity of ceftaroline against serotyped Streptococcus pneumoniae isolates from Europe and South Africa associated with community-acquired bacterial pneumonia (2007–08). J Antimicrob Chemother. 2012;67(6):1408–12.PubMedCrossRef
41.
Doern GV, Richter S, Heilmann K, et al. In vitro activity of ceftaroline against Staphylococcus aureus (SA) from consecutive US nationwide surveillance programs, 2009 and 2011 (abstract no. C2-126 plus poster). 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 9–12 Sept 2012; San Francisco (CA).
42.
Richter SS, Heilmann KP, Dohrn CL, et al. Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009. Antimicrob Agents Chemother. 2011;55(9):4154–60.PubMedCrossRef
43.
Doern GV, Diekema DJ, Heilmann KP, et al. In vitro activity of ceftaroline against clinical isolates of Streptococcus pneumoniae recovered in 43 US medical centers during 2010–2011. Antimicrob Agents Chemother. 2012;56(6):3406–8.PubMedCrossRef
44.
Rossolini GM, Livermore DM, Díaz-Regañón J, et al. Epidemiology and resistance among bacteria from adults with community-acquired pneumonia in Europe: results from PREMIUM ceftaroline study (abstract no. P2017 plus poster). 23rd European Congress of Clinical Microbiology and Infectious Disease; 27–30 Apr 2013; Berlin.
45.
Livermore DM, Canton Moreno R, Mushtaq S, et al. Epidemiology and resistance among bacteria from adults with complicated skin and soft tissue infections in Europe: the PREMIUM ceftaroline surveillance study (abstract no. P2042 plus poster). 23rd European Congress of Clinical Microbiology and Infectious Disease; 27–30 Apr 2013; Berlin.
46.
CLSI. Performance standards for antimicrobial susceptibility testing: twenty-third informational supplement. 2013. CLSI document M100-S23. Clinical Laboratory Standards Institute, Wayne (PA).
47.
48.
DeLeo FR, Otto M, Kreiswirth BN, et al. Community-associated meticillin-resistant Staphylococcus aureus. Lancet. 2010;375(9725):1557–68.PubMedCrossRef
49.
Otter JA, French GL. Molecular epidemiology of community-acquired meticillin-resistant Staphylococcus aureus in Europe. Lancet Infect Dis. 2010;10(4):227–39.PubMedCrossRef
50.
Chua K, Laurent F, Coombs G, et al. Antimicrobial resistance: not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician’s guide to community MRSA—its evolving antimicrobial resistance and implications for therapy. Clin Infect Dis. 2011;52(1):99–114.PubMedCrossRef
51.
Mendes RE, Tsakris A, Sader HS, et al. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. J Antimicrob Chemother. 2012;67(6):1321–4.PubMedCrossRef
52.
Alm R, Lahiri S, Sader HS, et al. Molecular characterization of Staphylococcus aureus isolates that are non-susceptible to ceftaroline isolated during the 2010 surveillance programme (abstract O282). 23rd European Congress of Clinical Microbiology and Infectious Disease; 27–30 Apr 2013; Berlin.
53.
Sader HS, Fritsche TR, Kaniga K, et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother. 2005;49(8):3501–12.PubMedCrossRef
54.
Saravolatz L, Pawlak J, Johnson L. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2010;54(7):3027–30.PubMedCrossRef
55.
Jones RN, Flamm RK, Sader HS. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin or vancomycin from USA hospitals (2008–2011) (abstract no. 831 plus poster). 49th Annual Meeting of the Infectious Diseases Society of America; 17–21 Oct 2012; San Diego (CA).
56.
Biek D, Critchley IA, Riccobene TA, et al. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity. J Antimicrob Chemother. 2010;65(Suppl. 4):iv9–16.
57.
Jones RN, Sader HS, Stilwell MG, et al. Ceftaroline activity tested against uncommonly isolated Gram-positive pathogens (2008–2011) (abstract no. P1621 plus poster). 23rd European Congress of Clinical Microbiology and Infectious Disease; 27–30 Apr 2013; Berlin.
58.
Patel SN, Pillai DR, Pong-Porter S, et al. In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008. J Antimicrob Chemother. 2009;64(3):659–60.PubMedCrossRef
59.
McGee L, Biek D, Ge Y, et al. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2009;53(2):552–6.PubMedCrossRef
60.
Fenoll A, Aguilar L, Robledo O, et al. In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime. Antimicrob Agents Chemother. 2008;52(11):4209–10.PubMedCrossRef
61.
Ge Y, Biek D, Talbot GH, et al. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother. 2008;52(9):3398–407.PubMedCrossRef
62.
Mushtaq S, Warner M, Ge Y, et al. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother. 2007;60(2):300–11.PubMedCrossRef
63.
Snydman DR, Jacobus NV, McDermott LA. In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother. 2011;55(1):421–5.PubMedCrossRef
64.
Citron DM, Tyrrell KL, Merriam CV, et al. In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria. Antimicrob Agents Chemother. 2010;54(4):1627–32.PubMedCrossRef
65.
Vidaillac C, Leonard SN, Rybak MJ. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob Agents Chemother. 2009;53(11):4712–7.PubMedCrossRef
66.
Zhanel GG, Rossnagel E, Nichol K, et al. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model. J Antimicrob Chemother. 2011;66(6):1301–5.PubMedCrossRef
67.
Noel AR, Tomaselli S, Elliott H, et al. Antibacterial effect of ceftaroline against MRSA and VISA strains studied in an in vitro pharmacokinetic model of infection (abstract no. P795). 21st European Congress of Clinical Microbiology and Infectious Diseases; 7–10 May 2011; Milan.
68.
Steed M, Vidaillac C, Rybak MJ. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2011;55(7):3522–6.PubMedCrossRef
69.
Zhanel GG, Yachison C, Nichol K, et al. Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model. J Antimicrob Chemother. 2012;67(7):1706–11.PubMedCrossRef
70.
Steed ME, Vidaillac C, Winterfield P, et al. Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2012;56(5):2691–5.PubMedCrossRef
71.
Pankuch GA, Appelbaum PC. Postantibiotic effect of ceftaroline against gram-positive organisms. Antimicrob Agents Chemother. 2009;53(10):4537–9.PubMed
72.
Vidaillac C, Leonard SN, Sader HS, et al. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53(6):2360–6.PubMedCrossRef
73.
Schaadt RD, Sweeney DA, Biek D, et al. In vitro evaluation of the antibacterial activity of ceftaroline in combination with other antibacterial agents (abstract no. E-279). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17–21 Sept 2007; Chicago (IL).
74.
Vidaillac C, Leonard SN, Rybak MJ. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates. Int J Antimicrob Agents. 2010;35(6):527–30.PubMedCrossRef
75.
Jacqueline C, Amador G, Batard E, et al. Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. J Antimicrob Chemother. 2011;66(4):863–6.PubMedCrossRef
76.
Jacqueline C, Caillon J, Le Mabecque V, et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother. 2007;51(9):3397–400.PubMedCrossRef
77.
Jacqueline C, Caillon J, Le Mabecque V, et al. In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and vancomycin. Antimicrob Agents Chemother. 2009;53(12):5300–2.PubMedCrossRef
78.
Jacqueline C, Amador G, Caillon J, et al. Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. J Antimicrob Chemother. 2010;65(8):1749–52.PubMedCrossRef
79.
Croisier-Bertin D, Piroth L, Charles P-E, et al. Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing. Antimicrob Agents Chemother. 2011;55(7):3557–63.PubMedCrossRef
80.
Cottagnoud P, Acosta F, Biek D, et al. Ceftaroline fosamil against penicillin-sensitive (PS) and penicillin-resistant (PR) Streptococcus pneumoniae in an experimental rabbit meningitis model (abstract no. B-702). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 12–15 Sept 2010; Boston (MA).
81.
Cottagnoud P, Stucki A, Accosta F, et al. Ceftaroline is superior to cefepime against a Klebsiella pneumoniae strain an experimental rabbit meningitis model (abstract no. 1569). 20th Annual European Congress of Clinical Microbiology and Infectious Diseases; 10–13 Apr 2010; Vienna.
82.
Keel RA, Crandon JL, Nicolau DP. Efficacy of human simulated exposures of ceftaroline administered at 600 mg every 12 h against phenotypically diverse Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2011;55(9):4028–32.PubMedCrossRef
83.
Bhalodi AA, Crandon JL, Biek D, et al. Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model. Antimicrob Agents Chemother. 2012;56(12):6160–5.PubMedCrossRef
84.
Housman ST, Keel RA, Crandon JL, et al. Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolates. Antimicrob Agents Chemother. 2012;56(5):2576–80.PubMedCrossRef
85.
Clark C, McGhee P, Appelbaum PC, et al. Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria. Antimicrob Agents Chemother. 2011;55(5):2344–51.PubMedCrossRef
86.
Hinshaw RR, Schaadt RD, Murray B, et al. Spontaneous mutation frequency and serial passage resistance development studies with ceftaroline (CPT) (abstract no. C1-185 plus poster). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Infectious Diseases Society of America; 25–28 Oct 2008; Washington (DC).
87.
Mushtaq S, Livermore DM. AmpC induction by ceftaroline. J Antimicrob Chemother. 2010;65(3):586–8.PubMedCrossRef
88.
Pfaller MA, Farrell DJ, Sader HS, et al. AWARE Ceftaroline Surveillance Program (2008–2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clinical Infectious Diseases. 2012;55(Suppl. 3):S187–93.PubMedCrossRef
89.
Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1–12.PubMedCrossRef
90.
Andes D, Craig WA. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother. 2006;50(4):1376–83.PubMedCrossRef
91.
Van Wart SA, Ambrose PG, Rubino CM, et al. Use of ceftaroline against Streptococcus pneumoniae: pharmacokinetic-pharmacodynamic target attainment analysis to evaluate susceptibility test interpretive criteria (abstract no. A2-549). 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 17–20 Sept 2011; Chicago (IL).
92.
Bhavnani SM, Van Wart SA, Rubino CM, et al. Pharmacokinetic-pharmacodynamic target attainment analysis to evaluate susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus (abstract no. A2-553). 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 17–20 Sept 2011; Chicago (IL).
93.
Bhavnani SM, Hammel JP, Van Wart SA, et al. Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with complicated skin and skin structure infection (abstract no. A2-552). 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 17–20 Sept 2011; Chicago (IL).
94.
Bhavnani SM, Hammel JP, Van Wart SA, et al. Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired pneumonia (abstract no. A2-551). 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 17–20 Sept 2011; Chicago (IL).
95.
Ge Y, Redman R, Floren L, et al. The pharmacokinetics (PK) and safety of ceftaroline (PPI-0903M) in healthy subjects receiving multiple-dose intravenous (IV) infusions (abstract no. A-1937). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 27–30 Sept 2006; San Francisco (CA).
96.
Riccobene T, Jakate A, Rank D, et al. Open-label pharmacokinetic, safety, and tolerability study of single intravenous doses of ceftaroline in healthy elderly and healthy young adult subjects (abstract no. 3-161). 44th Annual Midyear Clinical Meeting of the American Society of Health-System Pharmacists; 6–10 Dec 2009; Las Vegas (NV).
97.
Riccobene T, Fang E, Thye D. An open-label pharmacokinetic (PK), safety, and tolerability study of single intravenous (IV) doses of ceftaroline (CPT) in subjects with normal renal function or severe renal impairment (abstract no. A1-003). 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12–15 Sept 2009; San Francisco (CA).
98.
Ge Y, Thye D, Liao S, et al. Pharmacokinetics (PK) of ceftaroline (PPI-0903) in subjects with mild or moderate renal impairment (RI) (abstract A-1039). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 27–30 Sept 2006; San Francisco (CA).
99.
Riccobene T, Jakate A, Rank D, et al. An open-label, pharmacokinetic, safety and tolerability study of single-dose intravenous ceftaroline in subjects with end-stage renal disease on intermittent haemodialysis (abstract no. P1455). Clin Microbiol Infect. 2009;15(Suppl. S4):S407.
100.
Van Wart SA, Reynolds DK, Khariton T, et al. Impact of concomitant medication use on the pharmacokinetics of ceftaroline in patients with complicated skin and skin structure infections or community-acquired pneumonia (abstract no. A2-548). 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 17–20 Sept 2011; Chicago (IL).
101.
Corey GR, Wilcox MH, Talbot GH, et al. CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl. 4):iv41–51.
102.
Wilcox MH, Corey GR, Talbot GH, et al. CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl. 4):iv53–iv65.
103.
File TM, Jr., Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl. 3):iii19–32.
104.
Low DE, File TM, Jr., Eckburg PB, et al. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl. 3):iii33-44.
105.
Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51(6):641–50.PubMedCrossRef
106.
File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis. 2010;51(12):1395–405.PubMedCrossRef
107.
Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl. 4):iv67–71.
108.
Rank DR, Friedland HD, Laudano JB. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl. 3):iii53–9.
109.
Rank D, Baculik T, Eckburg PB, et al. Integrated safety analysis of CANVAS and FOCUS studies: randomised, double-blinded, phase 3 studies of ceftaroline versus comparators in complicated skin and skin structure infection and community-acquired bacterial pneumonia (abstract no. P1531 plus poster). Clin Microbiol Infect. 2011;17:S437.
110.
111.
Panagiotidis G, Backstrom T, Asker-Hagelberg C, et al. Effect of ceftaroline on normal human intestinal microflora. Antimicrob Agents Chemother. 2010;54(5):1811–4.PubMedCrossRef
112.
Riccobene TA, Rekeda L, Rank D, et al. Evaluation of the effect of a supratherapeutic dose of intravenous ceftaroline fosamil on the corrected QT interval. Antimicrob Agents Chemother. 2013;57(4):1777–83.PubMedCrossRef
113.
Leekha S, Terrell CL, Edson RS. General principles of antibiotic therapy. Mayo Clin Proc. 2011;86(2):156–67.PubMedCrossRef
114.
Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis. 2008;47(Suppl. 1):S3–13.PubMedCrossRef
115.
Shorr AF. Epidemiology and economic impact of meticillin-resistant Staphylococcus aureus: review and analysis of the literature. Pharmacoeconomics. 2007;25(9):751–68.PubMedCrossRef
116.
Lode HM. Clinical impact of antibiotic-resistant Gram-positive pathogens. Clin Microbiol Infect. 2009;15(3):212–7.PubMedCrossRef
117.
Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18–55.PubMedCrossRef
118.
Nathwani D, Morgan M, Masterton R, et al. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother. 2008;61(5):976–94.PubMedCrossRef
119.
Moellering RC, Jr. The problem of complicated skin and skin structure infections: the need for new agents. J Antimicrob Chemother. 2010;65(Suppl. 4):iv3–8.
120.
Nguyen HM, Graber CJ. Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer? J Antimicrob Chemother. 2010;65:24–36.PubMedCrossRef
121.
Stryjewski ME, Corey GR. New treatments for methicillin-resistant Staphylococcus aureus. Curr Opin Crit Care. 2009;15(5):403–12.PubMedCrossRef
122.
123.
124.
125.
Moet GJ, Jones RN, Biedenbach DJ, et al. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1998–2004). Diagn Microbiol Infect Dis. 2007;57:7–13.PubMedCrossRef
126.
Jones RN, Jacobs MR, Sader HS. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int J Antimicrob Agents. 2010;36(3):197–204.PubMedCrossRef
127.
Pillar C, Deane J, Sahm DF. High rates of multidrug-resistant Steptococcus pneumoniae in Europe. Pneumococcal activity profile from GLOBAL 6 surveillance (2009–2010) (abstract no. O418). 21st European Congress of Clinical Microbiology and Infectious Diseases; 7–10 May 2011; Milan.
128.
Garau J, Blasi F, Medina J, et al. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010–2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics (REACH study) (poster P689). 22nd European Congress of Clinical Microbiology and Infectious Diseases; 31 Mar–3 Apr 2012; London.
129.
Ostermann H, Blasi F, Medina J, et al. Health economic analysis of current clinical management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010–2011) (REACH study): use of resources and consequences of treatment failure (poster P690). 22nd European Congress of Clinical Microbiology and Infectious Diseases; 31 Mar–3 Apr 2012; London.
130.
Blasi F, Ostermann H, Medina J, et al. Current management of patients hospitalized with community-acquired pneumonia across Europe (2010–2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics (REACH study) (abstract plus oral presentation 0174). 22nd European Congress of Clinical Microbiology and Infectious Diseases; 31 Mar–3 Apr 2012; London.
131.
Ostermann H, Garau J, Medina J, et al. Health economic analysis of current clinical management of patients hospitalized with community-acquired pneumonia across Europe (2010-2011) (REACH study): use of resources and consequences of treatment failure (abstract plus oral presentation 0175). 22nd European Congress of Clinical Microbiology and Infectious Diseases; 31 Mar–3 Apr 2012; London.
132.
Blasi FB, Ostermann H, Racketa J, et al. Early versus later response to treatment in patients with community-acquired pneumonia (CAP): an analysis of clinical outcomes and resource use from the REACH study (abtract no. P2019 plus poster). 23rd European Congress of Clinical Microbiology and Infectious Disease; 27–30 Apr 2013; Berlin.
133.
Castanheira M, Sader HS, Farrell DJ. Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more beta-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types. Antimicrob Agents Chemother. 2012;56(9):4779–85.PubMedCrossRef
134.
Sader HS, Castanheira M, Jones RN. Antimicrobial spectrum and potency of ceftaroline-avibactam when tested against bacterial isolates from complicated urinary tract infections in the United States (abstract no. P1444). 22nd European Congress of Clinical Microbiology and Infectious Diseases; 31 Mar–3 Apr 2012; London.
135.
Maselli DJ, Fernandez JF, Whong CY, et al. Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia. Infect Drug Resist. 2012;5:43–51.PubMed
136.
Friedland HD, O’Neal T, Biek D, et al. CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2012;56(5):2231–6.PubMedCrossRef
137.
British Thoracic Society Community Acquired Pneumonia in Adults Guideline Group. Guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl. III):iii1–iii55.
138.
Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections—summary. Clin Microbiol Infect. 2011;17(Suppl. 6):1–24.PubMedCrossRef
139.
Mandell L, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27–72.PubMedCrossRef
140.
Shorr AF, Khollef M, Eckburg PB, et al. Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials. Diagn Microbiol Infect Dis. 2013;75:298–303.PubMedCrossRef
141.
Eckburg PB, Friedland HD, Llorens L, et al. Day 4 clinical response of ceftaroline fosamil versus ceftriaxone for community-acquired bacterial pneumonia. Infect Dis Clin Pract. 2012;20(4):254–60.CrossRef
142.
Cooke JE, Tanaka MF, Alapat PM, et al. Staphylococcus aureus as a cause of severe community-acquired pneumonia. Chest. 2010;138(4_meetingabstracts):736A.
143.
Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Prevalence of methicillin-resistant staphylococcus aureus as an etiology of community-acquired pneumonia. Clin Infect Dis. 2012;54(8):1126–33.PubMedCrossRef
144.
Santos P, Smith A, Jandourek A, et al. Ceftaroline fosamil for the treatment of complicated skin and skin structure infections (cSSTI) including special risk groups: CAPTURE year 1 findings (abstract P845 plus poster). 23rd European Congress of Clinical Microbiology and Infectious Disease; 27–30 Apr 2013; Berlin.
145.
Udeani G, Jandourek A, Li Y, et al. CAPTURE: ceftaroline fosamil for the treatment of community acquired bacterial pneumonia (CABP): year 1 (abstract A1688). American Thoracic Society 2013 International Conference; 17–22 May 2013; Philadelphia (PA).
146.
Jandourek A, Udeani G, Smith A, et al. CAPTURE study experience in patients with community acquired pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA) and treatment with ceftaroline (abstract no. P841 plus poster). 23rd European Congress of Clinical Microbiology and Infectious Disease; 27–30 Apr 2013; Berlin.
147.
Medic G, Karabis A, Borrill J, et al. Efficacy of ceftaroline fosamil and other intravenous antibiotics in the treatment of community-acquired pneumonia (CAP): a network meta-analysis (NMA) (abstract no. 38645 plus poster). International Society for Pharmacoeconomics and Outcomes Research: 15th Annual European Congress; 3–7 Nov 2012; Berlin.
148.
Medic G, Karabis A, Borrill J, et al. Efficacy of ceftaroline fosamil and other intravenous antibiotics in the treatment of complicated skin and soft tissue infections (cSSTIs): a network meta-analysis (NMA) (abstract no. 38551 plus poster). International Society for Pharmacoeconomics and Outcomes Research: 15th Annual European Congress; 3–7 Nov 2012; Berlin.
149.
150.
151.
Lodise T, Su Y, Tourkodimitris S, et al. Medical resource utilization (MRU) for hospitalized community-acquired pneumonia (CAP) treated with ceftaroline (CPT) fosamil or ceftriaxone (CRO) (abstract no. O-2217). 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12–15 Sept 2010; Boston (MA).
Metadata
Title
Ceftaroline Fosamil: A Review of its Use in the Treatment of Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia
Author
James E. Frampton
Publication date
01-07-2013
Publisher
Springer International Publishing
Published in
Drugs / Issue 10/2013
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-013-0075-6

Other articles of this Issue 10/2013

Drugs 10/2013 Go to the issue

Review Article

A Reappraisal of the Risks and Benefits of Treating to Target with Cholesterol Lowering Drugs

Leading Article

Intermittent Claudication: New Targets for Drug Development

Adis Drug Evaluation

Crofelemer: A Review of its Use in the Management of Non-Infectious Diarrhoea in Adult Patients with HIV/AIDS on Antiretroviral Therapy

Systematic Review

Efficacy and Safety of Botulinum Toxin A Intradetrusor Injections in Adults with Neurogenic Detrusor Overactivity/Neurogenic Overactive Bladder: A Systematic Review

Leading Article

Vaccine Development for Tuberculosis: Current Progress

Adis Drug Evaluation

Abatacept: A Review of its Use in the Management of Rheumatoid Arthritis